FINAL Q4 2010 Earnings Press Release - Baxter
FINAL Q4 2010 Earnings Press Release - Baxter
FINAL Q4 2010 Earnings Press Release - Baxter
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
BAXTER REPORTS 4th QUARTER FINANCIAL RESULTS – Page 2<br />
in the prior-year period. Adjusted earnings per diluted share increased 8 percent<br />
to $1.11 per diluted share from $1.03 reported in the fourth quarter of 2009.<br />
These results were in line with the company’s previously issued earnings<br />
guidance of $1.09 to $1.11 per diluted share.<br />
Worldwide sales in the fourth quarter totaled $3.5 billion and increased<br />
1 percent over the same period last year. Excluding the impact of foreign<br />
currency, worldwide sales advanced 3 percent. Sales within the United States<br />
increased by more than 1 percent to $1.4 billion and international sales of<br />
$2.1 billion were comparable to the prior-year period. Excluding the impact of<br />
foreign currency, international sales increased 3 percent.<br />
By business, BioScience revenues exceeded $1.5 billion and increased<br />
1 percent from the comparable prior-year period. Excluding the impact of foreign<br />
currency, BioScience sales increased 4 percent. Contributing to this performance<br />
was strong demand for GAMMAGARD LIQUID [Immune Globulin Intravenous<br />
(Human)] (marketed as KIOVIG outside of the United States), several specialty<br />
plasma-based therapeutics, and biosurgery products, resulting in double-digit<br />
sales growth across these product categories. This strength was partially offset<br />
by the expected decline in recombinant protein and vaccine revenues.<br />
Medication Delivery sales also increased 1 percent to $1.3 billion (or<br />
3 percent excluding the impact of foreign currency), driven primarily by growth of<br />
intravenous therapies (including the company’s parenteral nutrition products),<br />
injectable drugs and anesthesia products. Renal sales of $626 million were<br />
comparable to the prior-year period (and increased 1 percent excluding the<br />
impact of foreign currency), as the company continued to post solid gains in